Financial News

Medexus to Present at Raymond James Human Health Innovation Conference

Products You May Like

TORONTO, CHICAGO and MONTREAL, June 14, 2021 (GLOBE NEWSWIRE) — Medexus Prescribed drugs Inc. (the “Firm” or “Medexus”) (TSXV: MDP) (OTCQX: MEDXF) (Frankfurt: P731)introduced right now that it will likely be presenting on the Raymond James Human Well being Innovation Convention on June 21st, 2021.

Ken d’Entremont, Chief Government Officer, and Roland Boivin, Chief Monetary Officer, will current a Firm overview and supply a enterprise replace. The presentation can be webcast dwell and obtainable for replay on the Firm’s web site at

Raymond James Human Well being Innovation Convention
Date: Monday, June 21, 2021
Time: 2:40 P.M. Japanese Time

Along with the presentation, administration can be taking part in digital one-on-one conferences all through the convention. traders ought to contact their Raymond James representatives to schedule a gathering.

About Medexus

Medexus is a number one revolutionary and uncommon illness firm with a powerful North American business platform. From a basis of confirmed greatest at school merchandise we’re constructing a extremely differentiated firm with a portfolio of revolutionary and excessive worth orphan and uncommon illness merchandise that can underpin our progress for the following decade. The Firm’s imaginative and prescient is to supply the perfect healthcare merchandise to healthcare professionals and sufferers, by way of our core values of High quality, Innovation, Buyer Service and Teamwork. Medexus Prescribed drugs is concentrated on the therapeutic areas of auto-immune illness, hematology, and allergy. The Firm’s main merchandise are: Rasuvo™ and Metoject®, a singular formulation of methotrexate (auto-pen and pre-filled syringe) designed to deal with rheumatoid arthritis and different auto-immune ailments; IXINITY®, an intravenous recombinant issue IX therapeutic to be used in sufferers 12 years of age or older with Hemophilia B – a hereditary bleeding dysfunction characterised by a deficiency of clotting issue IX within the blood, which is important to regulate bleeding; and Rupall®, an revolutionary prescription allergy medicine with a singular mode of motion.

For extra data, please contact:

Ken d’Entremont, Chief Government Officer
Medexus Prescribed drugs Inc.
Tel.: 905-676-0003

Roland Boivin, Chief Monetary Officer
Medexus Prescribed drugs Inc.
Tel.: 514-344-8765

Investor Relations (U.S.):
Crescendo Communications, LLC
Tel: +1-212-671-1020
Electronic mail:

Investor Relations (Canada):
Tina Byers
Adelaide Capital
Tel: 905-330-3275

Primary Logo

Products You May Like